Beyond its diagnostic role in CIS, HER2 alone or in combination with other agents may be the leading actor of intravesical targeted therapies, including ADCs [33,34], in order to supply an alternative bladder-sparing approach in the subset of BCG-refractory CIS patients otherwise amenable to cystectomy [31,34]. This evidence concerns the gene ERBB2 and in situ carcinoma.